J
Jae Hoon Lee
Researcher at Gachon University
Publications - 229
Citations - 5008
Jae Hoon Lee is an academic researcher from Gachon University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 30, co-authored 218 publications receiving 4097 citations. Previous affiliations of Jae Hoon Lee include Green Cross International & Charles R. Drew University of Medicine and Science.
Papers
More filters
Journal ArticleDOI
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesús F. San-Miguel,V. Hungria,Sung-Soo Yoon,Meral Beksac,Meletios A. Dimopoulos,Ashraf Elghandour,Wiesław Wiktor Jędrzejczak,Andreas Günther,Thanyaphong Na Nakorn,Noppadol Siritanaratkul,Paolo Corradini,Suporn Chuncharunee,Je-Jung Lee,Robert L. Schlossman,Tatiana Shelekhova,Kwee Yong,Daryl Tan,Tontanai Numbenjapon,Jamie Cavenagh,Jian Hou,Richard Leblanc,Hareth Nahi,Lugui Qiu,Hans Salwender,Stefano Pulini,Philippe Moreau,Krzysztof Warzocha,Darrell White,Joan Bladé,Wenming Chen,Javier de la Rubia,Peter Gimsing,Sagar Lonial,Jonathan L. Kaufman,Enrique M. Ocio,Ljupco Veskovski,Sang Kyun Sohn,Ming Chung Wang,Jae Hoon Lee,Hermann Einsele,Monika Sopala,Claudia Corrado,Bourras Rezki Bengoudifa,Florence Binlich,Paul G. Richardson +44 more
TL;DR: Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone and the proportion of patients achieving an overall response did not differ between treatment groups.
Journal ArticleDOI
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal,Paul G. Richardson,S. Vincent Rajkumar,Jesús F. San-Miguel,Meral Beksac,Ivan Spicka,Xavier Leleu,Fredrik Schjesvold,Fredrik Schjesvold,Philippe Moreau,Meletios A. Dimopoulos,Jeffrey Shang Yi Huang,Jiri Minarik,Michele Cavo,H. Miles Prince,Sandrine Macé,Kathryn P. Corzo,Frank Campana,Solenn Le-Guennec,Franck Dubin,Kenneth C. Anderson,Vincent Rajkumar,Simon J. Harrison,Wojt Janowski,Ian Kerridge,Andrew Spencer,Michel Delforge,Karel Fostier,Philip Vlummens,Ka Lung Wu,Richard Leblanc,Michel Pavic,Michael Sebag,Roman Hájek,Vladimir Maisnar,Ludek Pour,Henrik Gregersen,Lotfi Benbouker,Denis Caillot,Martine Escoffre-Barbe,Thierry Facon,Laurent Frenzel,Cyrille Hulin,Lionel Karlin,Brigitte Kolb,Brigitte Pegourie,Aurore Perrot,Mourad Tiab,Laure Vincent,Dietger Niederwieser,Achilles Anagnostopoulos,Sosana Delimpasi,Marie Christine Kyrtsonis,Anargyros Symeonidis,Árpád Illés,Gabor Mikala,Zsolt Nagy,Sara Bringen,Paolo Corradini,Ciceri Fabio,Roberto M. Lemoli,Anna Marina Liberati,Chiara Nozzoli,Renato Zambello,Shinsuke Iida,Takashi Ikeda,Satoshi Iyama,Morio Matsumoto,Chihiro Shimazaki,Kazutaka Sunami,Kenshi Suzuki,Michihiro Uchiyama,Youngil Koh,Ki-Hyun Kim,Jae Hoon Lee,Chang-Ki Min,Hillary Blacklock,Hugh Goodman,AJ Neylon,David Simpson,Sebastian Grosicki,Artur Jurczyszyn,Adam Walter-Croneck,Krzysztof Warzocha,Luis Araujo,Claudia Moreira,Vadim A Doronin,Larisa P. Mendeleeva,Vladimir I. Vorobyev,Andrej Vranovsky,Adrian Alegre,Mercedes Gironella,Marta Sonia Gonzalez Perez,Carmen Montes,Enrique M. Ocio,Paula Rodriguez,Mats Hardling,Birgitta Lauri,Ming Chung Wang,Su Peng Yeh,Mutlu Arat,Fatih Demirkan,Zafer Gulbas,Sevgi Kalayoglu Besisik,Ihsan Karadogan,Tulin Tuglular,Ali Ünal,Filiz Vural,Jonathan Sive,Matthew Streetly,Kwee Yong,Jason Tache +111 more
TL;DR: The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and dexamethasone compared with pomidine and dexAMethas one in patients with relapsed and refractory multiple myeloma.
Journal ArticleDOI
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Paolo Ghia,Andrzej Pluta,Malgorzata Wach,Daniel Lysák,Tomas Kozak,Martin Simkovic,Polina Kaplan,Iryna Kraychok,Árpád Illés,Javier de la Serna,Sean Dolan,Phillip L. Campbell,Gerardo Musuraca,Abraham Jacob,Eric J. Avery,Jae Hoon Lee,Wei Liang,Priti Patel,Cheng Quah,Wojciech Jurczak +19 more
TL;DR: Acalabrutinib significantly improved PFS compared with I-R or B-R and has an acceptable safety profile in patients with R/R CLL.
Journal ArticleDOI
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A. Dimopoulos,Fredrik Schjesvold,Fredrik Schjesvold,Meral Beksac,Roman Hájek,Katja Weisel,Hartmut Goldschmidt,Vladimir Maisnar,Philippe Moreau,Chang-Ki Min,Agnieszka Pluta,Wee Joo Chng,Martin Kaiser,Martin Kaiser,Sonja Zweegman,Maria-Victoria Mateos,Andrew Spencer,Shinsuke Iida,Gareth J. Morgan,Kaveri Suryanarayan,Zhaoyang Teng,Tomas Skacel,Antonio Palumbo,Antonio Palumbo,Antonio Palumbo,Ajeeta B Dash,Neeraj Gupta,Richard Labotka,S. Vincent Rajkumar,Daniel Bar,Alfredo Basso,Dorotea Fantl,Simon He,Neomi Horvath,Cindy Lee,Phillip Rowlings,Kerry Taylor,Tara Cochrane,Fiona Kwok,Sundreswran Ramanathan,Hermine Agis,Niklas Zojer,Alain Kentos,Fritz Offner,Jan Van Droogenbroeck,Ka Lung Wu,Angelo Maiolino,Gracia Martinez,Karla Zanella,Marcelo Capra,Sergio Eduardo Alonso Araujo,Evzen Gregora,Ludek Pour,Vlastimil Scudla,Ivan Spicka,Niels Abildgaard,Niels Holmark Andersen,Bo Amdi Jensen,Carsten Helleberg,Torben Plesner,Morten Salomo,Asta Svirskaite,Richard Delarue,Igor Wolfgang Blau,Aneta Schieferdecker,Veronica Teleanu,Markus Munder,Christoph Röllig,Han-Juergen Salwender,Stephan Fuhrmann,Katja Weisel,Jan Duerig,Matthias Zeis,Stefan Klein,Peter Reimer,Christian Schmidt,Christof Scheid,Karin Mayer,Martin Hoffmann,Markus Sosada,Athanasios Dimopoulos,Sosana Delimpasi,Mary-Christine Kyrtsonis,Achilleas Anagnostopoulos,Zsolt Nagy,Árpád Illés,Miklos Egyed,Zita Borbényi,Gabor Mikala,Najib Dally,Netanel Horowitz,Odit Gutwein,Anatoly Nemets,Iuliana Vaxman,Olga Shvetz,Svetlana Trestman,Rosa Ruchlemer,Arnon Nagler,Tamar Tadmor,Ory Rouvio,Meir Preis,Michele Cavo,Luca De Rosa,Pellegrino Musto,Anna Maria Cafro,Patrizia Tosi,Massimo Offidani,Alessandro Corso,Giuseppe Rossi,Anna Marina Liberati,Alberto Bosi,Kenshi Suzuki,Chiaki Nakaseko,Takayuki Ishikawa,Morio Matsumoto,Hirokazu Nagai,Kazutaka Sunami,Takaaki Chou,Koichi Akashi,Naoki Takezako,Shotaro Hagiwara,Hyeon Seok Eom,Deog-Yeon Jo,Jin Seok Kim,Jae Hoon Lee,Sung-Soo Yoon,Dok Hyun Yoon,Kihyun Kim,Mark-David Levin,Edo Vellenga,Monique C. Minnema,Anders Waage,Einar Haukås,Sebastian Grosicki,Andrzej Pluta,Tadeusz Robak,Herlander Marques,Rui Bergantim,Fernando Campilho,Wee Joo Chng,Yeow Tee Goh,Andrew McDonald,Bernado Rapoport,Miguel Angel Álvarez Rivas,Felipe de Arriba de la Fuente,Yolanda González Montes,Jesus Martin Sanchez,María-Victoria Mateos,Albert Oriol Rocafiguera,Laura Rosiñol,Jesús F. San Miguel,Jaime Pérez de Oteyza,Cristina Encinas,Adrian Alegre-Amor,Ana López-Guía,Per Axelsson,Kristina Carlson,Olga Stromberg,Markus Hansson,Cecile Hveding Blimark,Rouven Mueller,Chih-Cheng Chen,Ta-Chih Liu,Shang-Yi Huang,Po-Nan Wang,Thanyaphong Na Nakorn,Kannadit Prayongratana,Ali Ünal,Hakan Goker,Mehmet Sönmez,Sybiryna Korenkova,Aristeidis Chaidos,Heather Oakervee,Hamdi Sati,Reuben Benjamin,Ashutosh D. Wechalekar,Mamta Garg,Karthik Ramasamy,Gordon Cook,Andrew D Chantry,Matthew W Jenner,Francis K. Buadi,Robert Berryman,Murali Janakiram +183 more
TL;DR: Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma.
Journal ArticleDOI
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia
Dae-Young Kim,Young-Don Joo,Sung-Nam Lim,Sung-Doo Kim,Jung-Hee Lee,Je-Hwan Lee,D.H. Kim,Kihyun Kim,Chul Won Jung,Inho Kim,Sung-Soo Yoon,Seonyang Park,Jae-Sook Ahn,Deok-Hwan Yang,Je-Jung Lee,Ho-Sup Lee,Yang Soo Kim,Yeung-Chul Mun,Hawk Kim,Jae Hoo Park,Joon Ho Moon,Sang Kyun Sohn,Sang Min Lee,Won Sik Lee,Kyoung Ha Kim,Jong-Ho Won,Myung Soo Hyun,Jinny Park,Jae Hoon Lee,Ho-Jin Shin,Joo-Seop Chung,Hyewon Lee,Hyeon-Seok Eom,Gyeong Won Lee,Young-Uk Cho,Seongsoo Jang,Chan-Jeoung Park,Hyun-Sook Chi,Kyoo-Hyung Lee +38 more
TL;DR: The combination of nilotinib with high-dose cytotoxic drugs was feasible, and it effectively achieved high cumulative complete molecular remission and HRFS rates.